BioCentury
ARTICLE | Clinical News

Genfit sinks on Phase II NASH data

March 28, 2015 1:50 AM UTC

Genfit S.A. (Euronext:GNFT) plunged EUR 22.54 (44%) to a six-month low of EUR 28.31 on Friday after its GFT505 missed the primary endpoint in the Phase IIb GOLDEN-505 trial to treat non-alcoholic steatohepatitis (NASH) (see BioCentury Extra, March 26).

Genfit said GFT505 met the primary endpoint of disease resolution after the company reanalyzed its data to account for baseline disease severity and trial site heterogeneity. The company plans to start a Phase III trial of the dual peroxisome proliferation activated receptor (PPAR) alpha and delta agonist by YE15. ...